Royalty Pharma Overview

  • Year Founded
  • 1996

Year Founded

  • Status
  • Public

  • Employees
  • 89

Employees

  • Stock Symbol
  • RPRX

Stock Symbol

  • Investments
  • 43

  • Share Price
  • $29.92
  • (As of Friday Closing)

Royalty Pharma General Information

Description

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Primary Industry
Other Pharmaceuticals and Biotechnology
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 110 East 59th Street
  • Suite 3300
  • New York, NY 10022
  • United States
+1 (212) 000-0000

Royalty Pharma Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Royalty Pharma Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$29.92 $30.03 $25.92 - $38.19 $13.4B 447M 2.63M $2.54

Royalty Pharma Financials Summary

In Thousands,
USD
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 20,440,950 20,440,950 26,591,243 26,106,932
Revenue 2,354,554 2,354,554 2,237,215 2,289,463
EBITDA 1,814,984 1,814,984 345,360 1,376,804
Net Income 1,134,834 1,134,834 42,832 619,728
Total Assets 16,381,851 16,381,851 16,813,466 17,515,865
Total Debt 6,135,285 6,135,285 7,116,322 7,096,070
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Royalty Pharma Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Royalty Pharma‘s full profile, request access.

Request a free trial

Royalty Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entit
Other Pharmaceuticals and Biotechnology
New York, NY
89 As of 2023
000.00
000000000 000.00

000000

re et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ul
000000000000000
New York, NY
00000 As of 0000
000.00
0000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Royalty Pharma Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pfizer (Pharmaceuticals) Corporation New York, NY 00000 000.00 0000 000.00
You’re viewing 1 of 1 competitors. Get the full list »

Royalty Pharma Patents

Royalty Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
FR-3124788-A1 Anti-projection protection device for rolling stock and assembly comprising such a device Pending 01-Jul-2021 0000000000 0
CA-3224444-A1 Splashguard device for a wheeled vehicle and assembly comprising such a device Pending 01-Jul-2021 0000000000
FR-3056235-A1 Device for controlling the access to the rolling machine and / or person to a predetermined zone Pending 20-Sep-2016 0000000000 0
FR-3056234-B1 Rolling gear and / or person access control device to a predetermined zone Inactive 20-Sep-2016 0000000000
FR-3056234-A1 Device for controlling the access to the rolling machine and / or person to a predetermined zone Active 20-Sep-2016 E01F13/044 0
To view Royalty Pharma’s complete patent history, request access »

Royalty Pharma Executive Team (19)

Name Title Board Seat Contact Info
Pablo Legorreta Founder, Chief Executive Officer & Chairman
Terrance Coyne Chief Financial Officer, Finance
Kristin Stafford Chief Accounting Officer & Senior Vice President
Jim Reddoch Ph.D Executive Vice President, Investments & Chief Scientific Officer
Sara Klymkowsky Executive, Research & Investments
You’re viewing 5 of 19 executive team members. Get the full list »

Royalty Pharma Board Members (10)

Name Representing Role Since
000000 0000000 00. Self Board Member 000 0000
00000000000 0000 0 Self Executive Vice President & Vice Chairman 000 0000
00000 0000000 General Atlantic Board Member 000 0000
00000 00 00000 00. Self Board Member 000 0000
0000000 000000 Self Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Royalty Pharma Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Royalty Pharma Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Royalty Pharma‘s full profile, request access.

Request a free trial

Royalty Pharma Investments & Acquisitions (43)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Amgen's olpasiran Royalty interest 09-Nov-2022 000000000 00000 Buildings and Property
Theravance Respiratory Company 20-Jul-2022 0000000000 00.00 Pharmaceuticals 00000 000
ApiJect 02-May-2022 00000 0000 00000 Medical Supplies 00000000
Cytokinetics 07-Jan-2022 0000 Pharmaceuticals
BioCryst Pharmaceuticals 22-Nov-2021 PIPE 0000 Pharmaceuticals 00000 000
You’re viewing 5 of 43 investments and acquisitions. Get the full list »

Royalty Pharma Subsidiaries (4)

Company Name Industry Location Founded
RPI 2019 Intermediate Finance Trust Other Capital Markets/Institutions New York, NY 2019
RPI Intermediate Finance Trust Other Capital Markets/Institutions New York, NY 0000
Erleada Pharmaceuticals Titusville, NJ
Orkambi Drug Discovery Boston, MA
To view Royalty Pharma’s complete subsidiaries history, request access »

Royalty Pharma ESG

Risk Overview

Risk Rating

Updated November, 09, 2023

28.04 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,605

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 870

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 386

Rank

00.00

Percentile

To view Royalty Pharma’s complete esg history, request access »

Royalty Pharma Exits (3)

Company Name Exit Date Exit Type Exit Size Status Buyers
Biohaven 07-Aug-2020 0000 00000 Completed
  • 0000000 000000
Biohaven 19-Jun-2018 0000 0000 Completed
  • 0000000 000000
Cypress Bioscience 15-Dec-2010 Buyout/LBO 00000 Completed
  • 2 buyers
To view Royalty Pharma’s complete exits history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »